Skip to content
MARKETS / NASDAQ / MGTX
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

MeiraGTx Holdings PLC MGTX

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$81.4M
▲ 144.6% YoY
$-114.2M
$-50.2M
In brief

What this company does

It has two viral vector production facilities for good manufacturing practices, internal plasmid production for GMP, and an in-house Quality Control hub for stability and release, all fit for Investigational New Drug application through commercial supply. It has also developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive expression of any transgene under the control of oral small molecules. As of December 31, 2025, the company had 403 employees, 400 of which were full-time employees, and none of its employees were subject to a collective bargaining agreement or represented by a trade or labor union. MeiraGTx Holdings plc was formed on May 1, 2018 under the laws of the Cayman Islands, and its predecessor, MeiraGTx Limited, a limited company under the laws of England and Wales, was formed on March 20, 2015.

Written from the business description in MeiraGTx Holdings plc's annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 81.4M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 81.4 · Net income -114.2
40M80M-50M-100M201720182019202020212022202320242025
Compound annual growth
+72.3%
+39.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +39.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−140 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -130.2% · Net -140.3%
-500%201720182019202020212022202320242025
ROE
FY2025 · ROE -368.2%
-200%-400%201720182019202020212022202320242025

Each USD of equity lost 368 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -50.2
-50M-100M201720182019202020212022202320242025

Total assetsUSD 244.4M
EquityUSD -5.8M
CashUSD 65.9M
Current ratio0.75×

Equity funds -2% of total assets.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.10.00.00.00.00.00.0··
Operating income $B−0.1−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B−0.1−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.00.0·0.00.00.0−0.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.10.0−0.1−0.0
EPS, diluted $−1.42−2.12−1.49−2.87−1.80−1.54−1.65−4.47−3.72
Dividend / sh $·········
Payout %·········
ROE %−368.2−143.5−65.7−85.5−37.5−27.0−40.3−491.9·
Shares out B0.080.080.060.050.040.040.040.030.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 40 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image